Charles Schwab’s Acumen Pharmaceuticals ABOS Stock Holding History

Charles Schwab’s Portfolio ABOS Stock Details ABOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-116,902	Closed	-$129K	–	3495
2025 Q1	$129K	Sell	116,902 -9,845	-8%	-$14.1K	﹤0.01%	3308
2024 Q4	$218K	Buy	126,747 +18,004	+17%	+$43.3K	﹤0.01%	3317
2024 Q3	$270K	Hold	108,743	–	–	﹤0.01%	3304
2024 Q2	$263K	Buy	+108,743	New	+$346K	﹤0.01%	3397
2022 Q2	–	Sell	-63,251	Closed	-$248K	–	3537
2022 Q1	$248K	Buy	63,251 +39,214	+163%	+$213K	﹤0.01%	3270
2021 Q4	$163K	Hold	24,037	–	–	﹤0.01%	3386
2021 Q3	$358K	Buy	+24,037	New	+$400K	﹤0.01%	3226

Other funds holding ABOS

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KIA

Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return

Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Charles Schwab's ABOS Position: Q2 2025 in Review

Charles Schwab sold out of Acumen Pharmaceuticals (ABOS) in Q2 2025, closing a stake of 116,902 shares — an estimated $129K sold.

Charles Schwab first reported a position in ABOS in Q3 2021 and held it in 7 quarters. The position peaked at $358K in Q3 2021. 71 funds tracked by Wall St. Rank hold ABOS as of Q2 2025.

Charles Schwab reported no remaining Acumen Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Charles Schwab sold 116,902 Acumen Pharmaceuticals shares in Q2 2025, an estimated $129K.
Charles Schwab first reported a position in Acumen Pharmaceuticals in Q3 2021 and held it in 7 quarters.
Charles Schwab's Acumen Pharmaceuticals position peaked at $358K in Q3 2021.
71 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q2 2025.

Based on Charles Schwab's 13F filing for Q2 2025, filed 12 Aug 2025.